WALTHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Steve Silvestro, currently serving as the Company’s Chief Executive Officer, to its Board of Directors, effective as of June 20, 2025. Mr. Silvestro joined the Company in 2019 and has been the Company’s CEO since March 2025, afte ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

OptimizeRx Corp. (OPRX) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisio ...

Commission File Number: 001-38543 OptimizeRx Corporation Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 o Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ (Exact name of registrant as specified in its charter) (State or other jurisdictio ...

OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 172.73%. A quarter ago, it was expected that this company would post earnings of $0.25 per share when it actually produced earnings of $0.30, delivering a surprise of 20%.Over the last four quarters, the com ...

OptimizeRx (OPRX) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Steve Silvestro - CEOEdward Stelmakh - CFO & COORyan Daniels - Group Head–Healthcare Technology and ServicesAndrew D’silva - SVP - Corporate FinanceDavid Grossman - Managing DirectorMax Michaelis - Equity Research AssociateConstantine Davides - Managing DirectorJeff Garro - Managing Director Conference Call Participants Richard Baldry - MD & Senior Research Analyst Operator Good afternoon, everyone, and thank you for joini ...

OptimizeRx (OPRX) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Speaker0 Good afternoon, everyone, and thank you for joining OptimizeRx First Quarter Fiscal twenty twenty five Earnings Conference Call. With us today is Chief Executive Officer, Steve Silvestro. He is joined by chief financial officer, Ed Stelmark, chief legal officer, Maureen Odens Ford, and senior vice president of corporate finance, Andrew DeSilva. At the conclusion of today's call, I will provide some important cautions regarding the for ...

OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance - Q1 revenue of $21.9 million, increasing 11% year-over-year - Q1 gross profit increased 9% year-over-year to $13.3 million - Increases full year 2025 guidance to a revenue range between $101 million and $106 million and adjusted EBITDA range between $13 million and $15 million WALTHAM, Mass. – May 12, 2025 – OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), a leading provider of healthcare technology solutions help ...

Q1 revenue of $21.9 million, increasing 11% year-over-yearQ1 gross profit increased 9% year-over-year to $13.3 millionIncreases full year 2025 guidance to a revenue range between $101 million and $106 million and adjusted EBITDA range between $13 million and $15 million WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and pati ...

WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and Governance (ESG) report for 2025. As a company focused on optimizing meaningful engagement opportunities at critical junctures of the healthcare journey, we remain dedicated to aligning our mission with our responsibiliti ...